Influenza Vaccination in Patients with Comorbidities

Several recent studies have investigated administration of influenza vaccination in patients with illnesses and comorbidities.

  • A study of high-dose inactivated influenza vaccine (IIV-HD), as compared to standard-dose vaccine (IIV-SD) in adults aged ≥65 years, found IIV-HD to be superior to IIV-SD. There was no significant evidence that baseline age, comorbidity, or frailty modified the efficacy of IIV-HD relative to IIV-SD.2
  • A study of patients with diabetes found that this population, which is considered a high-risk group during influenza season, can mount an antibody response to influenza vaccination (determined by both ELISA and hemagglutination inhibition [HAI] assays) that may confer protection against influenza infection.3
  • A recent review article found support for annual influenza vaccinations in patients with end stage renal disease (ESRD), as well as vaccination of their close contacts. Available studies have confirmed the safety and tolerability of inactivated vaccines.4